BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia
Published: 23 Jun 2020
Views: 293
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses BLIN-01 trial which looks at blinatumomab use during consolidation in adult patients with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia.
He outlines the trial design, results and toxicity profile.
Related Videos
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lo...
3 Dec 2018
